



Louisiana

Topical Corticosteroids

Policy # 00318

Original Effective Date: 05/22/2013

Current Effective Date: 05/10/2021

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the "Company"), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

When Services May Be Eligible for Coverage

Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:

- *Benefits are available in the member's contract/certificate, and*
- *Medical necessity criteria and guidelines are met.*

For Patients With "Step Therapy" (generic before brand) ONLY:

Based on review of available data, the Company may consider brand name topical corticosteroids [including, but not limited to Clobex[®] (clobetasol), Desonate[®] (desonide), Kenalog[®] (triamcinolone), Locoid Lipocream[®] (hydrocortisone), Impoyz[™] (clobetasol), Bryhali[™] (halobetasol), Lexette[™] (halobetasol), branded halobetasol foam, Duobrii[™] (halobetasol/tazarotene), Halog[®] (halcinonide), Olux E[®] (clobetasol), and Impeklo[™] (clobetasol)] to be **eligible for coverage**** when one of the below patient selection criteria is met:

Patient Selection Criteria

Coverage eligibility will be considered for brand name topical corticosteroids when one of the following criteria is met:

- Patient has tried and failed one generic prescription topical corticosteroid product for their current condition (e.g. clobetasol, desonide, triamcinolone, hydrocortisone, betamethasone); OR
- There is clinical evidence or patient history that suggests the generically available products will be ineffective or cause an adverse reaction to the patient.

When Services Are Considered Not Medically Necessary

Based on review of available data, the Company considers the use of brand name topical corticosteroids when patient selection criteria are not met or for usage not included in the above patient selection criteria to be **not medically necessary.****

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Topical Corticosteroids

Policy # 00318

Original Effective Date: 05/22/2013

Current Effective Date: 05/10/2021

For Patients With “Prior Authorization” ONLY:

Based on review of available data, the Company may consider Impoyz (clobetasol), Bryhali (halobetasol), Lexette (halobetasol), Duobrii (halobetasol/tazarotene), Impeklo (clobetasol), Wyzora^{®†} (calcipotriene/betamethasone), or branded halobetasol foam to be **eligible for coverage**** when the patient selection criteria are met:

Patient Selection Criteria:

Coverage eligibility will be considered for Impoyz (clobetasol), Bryhali (halobetasol), Lexette (halobetasol), Duobrii (halobetasol/tazarotene), Impeklo (clobetasol), Wyzora (calcipotriene/betamethasone), or branded halobetasol foam when the following criteria are met:

- Patient is greater than or equal to 18 years of age; AND
- Patient meets ONE of the following:
 - The requested drug is Impoyz and the patient meets ALL of the following:
 - Patient has a diagnosis of moderate to severe plaque psoriasis: AND
 - Patient has plaque psoriasis involvement on greater than 10% of body surface area (BSA) OR less than or equal to 10% BSA with plaque psoriasis involving areas that would significantly impact daily function (such as palms or soles of feet): AND
*(Note: This specific patient criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met).*
 - Patient has tried and failed (e.g. intolerance or inadequate response) TWO prescription GENERIC clobetasol propionate products for at least TWO weeks EACH unless there is clinical evidence or patient history that suggests the use of TWO prescription GENERIC clobetasol propionate products for at least TWO weeks EACH will be ineffective or cause an adverse reaction to the patient. Note: Generic clobetasol formulations include clobetasol propionate cream 0.05%, clobetasol propionate gel 0.05%, clobetasol propionate ointment 0.05%, clobetasol propionate emollient base cream 0.05%; AND
*(Note: This specific patient criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met).*

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Topical Corticosteroids

Policy # 00318

Original Effective Date: 05/22/2013

Current Effective Date: 05/10/2021

- Patient has tried and failed (e.g. intolerance or inadequate response) TWO of the following prescription GENERIC super high or high potency topical corticosteroids for at least TWO weeks EACH: betamethasone dipropionate 0.5% cream, lotion, or ointment; halobetasol propionate 0.5% cream or ointment; or desoximetasone cream, gel, or ointment, unless there is clinical evidence or patient history that suggests the use of the select prescription GENERIC super high or high potency topical corticosteroids for at least TWO weeks EACH will be ineffective or cause an adverse reaction to the patient; OR
*(Note: This specific patient criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met).*
- The requested drug is Impeklo and the patient meets ALL of the following:
 - Patient has a diagnosis of a corticosteroid-responsive dermatosis; AND
 - Patient has tried and failed (e.g. intolerance or inadequate response) TWO prescription GENERIC clobetasol propionate products for at least TWO weeks EACH unless there is clinical evidence or patient history that suggests the use of TWO prescription GENERIC clobetasol propionate products for at least TWO weeks EACH will be ineffective or cause an adverse reaction to the patient. Note: Generic clobetasol formulations include clobetasol propionate cream 0.05%, clobetasol propionate gel 0.05%, clobetasol propionate ointment 0.05%, clobetasol propionate emollient base cream 0.05%; AND
*(Note: This specific patient criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met).*
 - Patient has tried and failed (e.g. intolerance or inadequate response) TWO of the following prescription GENERIC super high or high potency topical corticosteroids for at least TWO weeks EACH: betamethasone dipropionate 0.5% cream, lotion, or ointment; halobetasol propionate 0.5% cream or ointment; or desoximetasone cream, gel, or ointment, unless there is clinical evidence or patient history that suggests the use of the select prescription GENERIC super high or high potency topical corticosteroids for at least TWO

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Topical Corticosteroids

Policy # 00318

Original Effective Date: 05/22/2013

Current Effective Date: 05/10/2021

weeks EACH will be ineffective or cause an adverse reaction to the patient;
OR

*(Note: This specific patient criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met).*

- The requested drug is Bryhali, Lexette, or branded halobetasol foam AND the patient meets ALL of the following:
 - Patient has a diagnosis of moderate to severe plaque psoriasis: AND
 - Patient has plaque psoriasis involvement on greater than 10% of body surface area (BSA) OR less than or equal to 10% BSA with plaque psoriasis involving areas that would significantly impact daily function (such as palms or soles of feet): AND
*(Note: This specific patient criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met).*
 - Patient has tried and failed (e.g. intolerance or inadequate response) TWO prescription GENERIC halobetasol propionate products for at least TWO weeks EACH unless there is clinical evidence or patient history that suggests the use of TWO prescription GENERIC halobetasol propionate products for at least TWO weeks EACH will be ineffective or cause an adverse reaction to the patient. Note: Generic halobetasol formulations include halobetasol propionate 0.05% cream and halobetasol propionate 0.05% ointment; AND
*(Note: This specific patient criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met).*
 - Patient has tried and failed (e.g. intolerance or inadequate response) TWO of the following prescription GENERIC super high or high potency topical corticosteroids for at least TWO weeks EACH: betamethasone dipropionate 0.5% cream, lotion, or ointment; clobetasol propionate 0.5% cream, foam, gel, lotion, ointment, shampoo, or solution; or desoximetasone cream, gel, or ointment, unless there is clinical evidence or patient history that suggests the use of the select prescription GENERIC super high or high potency topical corticosteroids for at least TWO weeks EACH will be ineffective or cause an adverse reaction to the patient; OR

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Topical Corticosteroids

Policy # 00318

Original Effective Date: 05/22/2013

Current Effective Date: 05/10/2021

*(Note: This specific patient criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met).*

- The requested drug is Duobrii and the patient meets ALL of the following:
 - Patient has a diagnosis of moderate to severe plaque psoriasis: AND
 - Patient has plaque psoriasis involvement on greater than 10% of body surface area (BSA) OR less than or equal to 10% BSA with plaque psoriasis involving areas that would significantly impact daily function (such as palms or soles of feet): AND

*(Note: This specific patient criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met).*
- Patient has tried and failed at least TWO prescription GENERIC halobetasol corticosteroid products for at least TWO weeks EACH unless there is clinical evidence or patient history that suggests the use of the required products will be ineffective or cause an adverse reaction to the patient. Prescription generic halobetasol products include: halobetasol propionate 0.05% cream and halobetasol propionate 0.05% ointment; AND
- (Note: This specific patient criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met).*
- Patient has tried and failed at least TWO of the following prescription GENERIC super high or high potency topical corticosteroid products for at least TWO weeks EACH unless there is clinical evidence or patient history that suggests the use of the required products will be ineffective or cause an adverse reaction to the patient. Prescription generic corticosteroid products include betamethasone dipropionate 0.5% cream, lotion, or ointment; clobetasol propionate 0.5% cream, foam, gel, lotion, ointment, shampoo, or solution; and desoximetasone cream, gel, or ointment. AND
- (Note: This specific patient criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met).*
- Patient has tried and failed TWO of the following GENERIC topical products for at least 4 weeks EACH unless there is clinical evidence or patient history

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Topical Corticosteroids

Policy # 00318

Original Effective Date: 05/22/2013

Current Effective Date: 05/10/2021

that suggests the use of the required products will be ineffective or cause an adverse reaction to the patient: generic calcipotriene, calcitrene, calcitriol, or tazarotene; OR

*(Note: This specific patient criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met).*

- The requested drug is Wynzora and the patient meets ALL of the following:
 - Patient has a diagnosis of moderate to severe plaque psoriasis: AND
 - Patient has plaque psoriasis involvement on greater than 10% of body surface area (BSA) OR less than or equal to 10% BSA with plaque psoriasis involving areas that would significantly impact daily function (such as palms or soles of feet): AND

*(Note: This specific patient criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met).*
- Patient has tried and failed at least TWO prescription GENERIC betamethasone corticosteroid products for at least TWO weeks EACH unless there is clinical evidence or patient history that suggests the use of the required products will be ineffective or cause an adverse reaction to the patient. Prescription generic betamethasone products include: betamethasone dipropionate 0.5% cream, lotion, or ointment; AND
- (Note: This specific patient criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met).*
- Patient has tried and failed at least TWO of the following prescription GENERIC super high or high potency topical corticosteroid products for at least TWO weeks EACH unless there is clinical evidence or patient history that suggests the use of the required products will be ineffective or cause an adverse reaction to the patient. Prescription generic corticosteroid products include halobetasol propionate 0.05% cream and ointment; clobetasol propionate 0.5% cream, foam, gel, lotion, ointment, shampoo, or solution; and desoximetasone cream, gel, or ointment. AND

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Topical Corticosteroids

Policy # 00318

Original Effective Date: 05/22/2013

Current Effective Date: 05/10/2021

*(Note: This specific patient criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met).*

- Patient has tried and failed TWO of the following GENERIC topical products for at least 4 weeks EACH unless there is clinical evidence or patient history that suggests the use of the required products will be ineffective or cause an adverse reaction to the patient: generic calcipotriene, calcitrene, calcitriol, or tazarotene; OR

*(Note: This specific patient criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met).*

When Services Are Considered Not Medically Necessary

Based on review of available data, the Company considers the use of Impoyz (clobetasol), Bryhali (halobetasol), Lexette (halobetasol), Duobrii (halobetasol/tazarotene), Wynzora (calcipotriene/betamethasone), or branded halobetasol foam when the patient has less than or equal to 10% of BSA impacted by plaque psoriasis when the plaque psoriasis does not involve areas that would significantly impact daily function and when the patient has not tried and failed the required prescription generic alternative products to be **not medically necessary.****

Based on review of available data, the Company considers the use of Impeklo (clobetasol) when the patient has not tried and failed the require prescription generic alternative products to be **not medically necessary.****

When Services Are Considered Investigational

Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.

Based on review of available data, the Company considers the use of Impoyz (clobetasol), Bryhali (halobetasol), Lexette (halobetasol), Duobrii (halobetasol/tazarotene), Wynzora (calcipotriene/betamethasone), and branded halobetasol foam for patients younger than 18 years of age or for any indication other than the treatment of moderate to severe plaque psoriasis to be **investigational.***

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Topical Corticosteroids

Policy # 00318

Original Effective Date: 05/22/2013

Current Effective Date: 05/10/2021

Based on review of available data, the Company considers the use of Impeklo (clobetasol) for patients younger than 18 years of age or for those without a diagnosis of a corticosteroid-responsive dermatosis to be **investigational**.*

For Patients With BOTH “Prior Authorization” AND “Step Therapy”:

Based on review of available data, the Company may consider brand name topical corticosteroids (including, but not limited to Clobex (clobetasol), Desonate (desonide), Kenalog (triamcinolone), Locoid Lipocream (hydrocortisone), Impoyz (clobetasol), Bryhali (halobetasol), Lexette (halobetasol), Duobrii (halobetasol/tazarotene), Impeklo (clobetasol), Wyzora (calcipotriene/betamethasone), branded halobetasol foam, Halog (halcinonide), and Olux E (clobetasol)) to be **eligible for coverage**** when one of the below patient selection criteria is met:

Patient Selection Criteria

Coverage eligibility will be considered for brand name topical corticosteroids when ALL of the specific drug’s criteria are met:

- For Impoyz requests ONLY:
 - Patient has a diagnosis of moderate to severe plaque psoriasis; AND
 - Patient is greater than or equal to 18 years of age; AND
 - Patient has plaque psoriasis involvement in greater than 10% of body surface area (BSA) OR less than or equal to 10% BSA with plaque psoriasis involving areas that would significantly impact daily function (such as palms or soles of feet); AND
*(Note: This specific patient criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met).*
 - Patient has tried and failed (e.g. intolerance or inadequate response) TWO prescription GENERIC clobetasol propionate products for at least TWO weeks EACH unless there is clinical evidence or patient history that suggests the use of TWO prescription GENERIC clobetasol propionate products for at least TWO weeks EACH will be ineffective or cause an adverse reaction to the patient. Note: Generic clobetasol formulations include clobetasol propionate cream 0.05%, clobetasol propionate gel 0.05%, clobetasol propionate ointment 0.05%, clobetasol propionate emollient base cream 0.05%; AND
*(Note: This specific patient criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met).*

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Topical Corticosteroids

Policy # 00318

Original Effective Date: 05/22/2013

Current Effective Date: 05/10/2021

- Patient has tried and failed (e.g. intolerance or inadequate response) TWO of the following prescription GENERIC super high or high potency topical corticosteroids for at least TWO weeks EACH: betamethasone dipropionate 0.5% cream, lotion, or ointment; halobetasol propionate 0.5% cream or ointment; or desoximetasone cream, gel, or ointment, unless there is clinical evidence or patient history that suggests the use of the select prescription generic super high or high potency topical corticosteroids for at least TWO weeks EACH will be ineffective or cause an adverse reaction to the patient.
*(Note: This specific patient criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met).*
- For Bryhali, Lexette, Duobrii, or branded halobetasol foam requests ONLY:
 - Patient has a diagnosis of moderate to severe plaque psoriasis; AND
 - Patient is greater than or equal to 18 years of age; AND
 - Patient has plaque psoriasis involvement in greater than 10% of body surface area (BSA) OR less than or equal to 10% BSA with plaque psoriasis involving areas that would significantly impact daily function (such as palms or soles of feet); AND
*(Note: This specific patient criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met).*
 - Patient has tried and failed (e.g. intolerance or inadequate response) TWO prescription GENERIC halobetasol propionate products for at least TWO weeks EACH unless there is clinical evidence or patient history that suggests the use of TWO prescription GENERIC halobetasol propionate products for at least TWO weeks EACH will be ineffective or cause an adverse reaction to the patient. Note: Generic halobetasol formulations include halobetasol propionate 0.05% cream and halobetasol propionate 0.05% ointment; AND
*(Note: This specific patient criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met).*
 - Patient has tried and failed (e.g. intolerance or inadequate response) TWO of the following prescription GENERIC super high or high potency topical corticosteroids for at least TWO weeks EACH: betamethasone dipropionate 0.5% cream, lotion, or ointment; clobetasol propionate 0.5% cream, foam, gel, lotion, ointment, shampoo, or solution; or desoximetasone cream, gel, or ointment, unless there is clinical evidence or patient history that suggests the use of the select prescription GENERIC

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Topical Corticosteroids

Policy # 00318

Original Effective Date: 05/22/2013

Current Effective Date: 05/10/2021

super high or high potency topical corticosteroids for at least TWO weeks EACH will be ineffective or cause an adverse reaction to the patient.

*(Note: This specific patient criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met).*

- For Duobrii requests ONLY:
 - Patient has a diagnosis of moderate to severe plaque psoriasis; AND
 - Patient is greater than or equal to 18 years of age; AND
 - Patient has plaque psoriasis involvement in greater than 10% of body surface area (BSA) OR less than or equal to 10% BSA with plaque psoriasis involving areas that would significantly impact daily function (such as palms or soles of feet); AND
*(Note: This specific patient criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met).*
 - Patient has tried and failed at least TWO prescription GENERIC halobetasol corticosteroid products for at least TWO weeks EACH unless there is clinical evidence or patient history that suggests the use of the required products will be ineffective or cause an adverse reaction to the patient. Prescription generic halobetasol products include: halobetasol propionate 0.05% cream and halobetasol propionate 0.05% ointment; AND
*(Note: This specific patient criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met).*
 - Patient has tried and failed at least TWO of the following prescription GENERIC super high or high potency topical corticosteroid products for at least TWO weeks EACH unless there is clinical evidence or patient history that suggests the use of the required products will be ineffective or cause an adverse reaction to the patient. Prescription generic corticosteroid products include betamethasone dipropionate 0.5% cream, lotion, or ointment; clobetasol propionate 0.5% cream, foam, gel, lotion, ointment, shampoo, or solution; and desoximetasone cream, gel, or ointment. AND
*(Note: This specific patient criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met).*
 - Patient has tried and failed TWO of the following GENERIC topical products for at least 4 weeks EACH unless there is clinical evidence or patient history that suggests the use of the required products will be ineffective or cause an adverse reaction to the patient: generic calcipotriene, calcitrene, calcitriol, or tazarotene.

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Topical Corticosteroids

Policy # 00318

Original Effective Date: 05/22/2013

Current Effective Date: 05/10/2021

*(Note: This specific patient criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met).*

- For Impeklo requests ONLY:
 - Patient has a diagnosis of a corticosteroid-responsive dermatosis; AND
 - Patient is greater than or equal to 18 years of age; AND
 - Patient has tried and failed (e.g. intolerance or inadequate response) TWO prescription GENERIC clobetasol propionate products for at least TWO weeks EACH unless there is clinical evidence or patient history that suggests the use of TWO prescription GENERIC clobetasol propionate products for at least TWO weeks EACH will be ineffective or cause an adverse reaction to the patient. Note: Generic clobetasol formulations include clobetasol propionate cream 0.05%, clobetasol propionate gel 0.05%, clobetasol propionate ointment 0.05%, clobetasol propionate emollient base cream 0.05%; AND
*(Note: This specific patient criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met).*
 - Patient has tried and failed (e.g. intolerance or inadequate response) TWO of the following prescription GENERIC super high or high potency topical corticosteroids for at least TWO weeks EACH: betamethasone dipropionate 0.5% cream, lotion, or ointment; halobetasol propionate 0.5% cream or ointment; or desoximetasone cream, gel, or ointment, unless there is clinical evidence or patient history that suggests the use of the select prescription GENERIC super high or high potency topical corticosteroids for at least TWO weeks EACH will be ineffective or cause an adverse reaction to the patient.
*(Note: This specific patient criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met).*
- For Wyzora requests ONLY:
 - Patient has a diagnosis of moderate to severe plaque psoriasis; AND
 - Patient has plaque psoriasis involvement on greater than 10% of body surface area (BSA) OR less than or equal to 10% BSA with plaque psoriasis involving areas that would significantly impact daily function (such as palms or soles of feet): AND
*(Note: This specific patient criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met).*
 - Patient has tried and failed at least TWO prescription GENERIC betamethasone corticosteroid products for at least TWO weeks EACH unless there is clinical

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Topical Corticosteroids

Policy # 00318

Original Effective Date: 05/22/2013

Current Effective Date: 05/10/2021

evidence or patient history that suggests the use of the required products will be ineffective or cause an adverse reaction to the patient. Prescription generic betamethasone products include: betamethasone dipropionate 0.5% cream, lotion, or ointment; AND

*(Note: This specific patient criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met).*

- Patient has tried and failed at least TWO of the following prescription GENERIC super high or high potency topical corticosteroid products for at least TWO weeks EACH unless there is clinical evidence or patient history that suggests the use of the required products will be ineffective or cause an adverse reaction to the patient. Prescription generic corticosteroid products include halobetasol propionate 0.05% cream and ointment; clobetasol propionate 0.5% cream, foam, gel, lotion, ointment, shampoo, or solution; and desoximetasone cream, gel, or ointment. AND

*(Note: This specific patient criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met).*

- Patient has tried and failed TWO of the following GENERIC topical products for at least 4 weeks EACH unless there is clinical evidence or patient history that suggests the use of the required products will be ineffective or cause an adverse reaction to the patient: generic calcipotriene, calcitrene, calcitriol, or tazarotene; OR

*(Note: This specific patient criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met).*

- For all other brand name topical corticosteroid requests:
 - The patient has tried and failed one generic prescription topical corticosteroid product for their current condition (e.g. clobetasol, desonide, triamcinolone, hydrocortisone, betamethasone); OR
 - There is clinical evidence or patient history that suggests the generically available products will be ineffective or cause an adverse reaction to the patient.

When Services Are Considered Not Medically Necessary

Based on review of available data, the Company considers the use of Impoyz (clobetasol), Bryhali (halobetasol), Lexette (halobetasol), Duobrii (halobetasol/tazarotene), Wyzora (calcipotriene/betamethasone) and branded halobetasol foam when the patient has less than or equal to 10% of BSA impacted by plaque psoriasis when the plaque psoriasis does not involve areas that

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Topical Corticosteroids

Policy # 00318

Original Effective Date: 05/22/2013

Current Effective Date: 05/10/2021

would significantly impact daily function and when the patient has not tried and failed the required prescription generic alternative products to be **not medically necessary.****

Based on review of available data, the Company considers the use of Impeklo (clobetasol) when the patient has not tried and failed the require prescription generic alternative products to be **not medically necessary.****

Based on review of available data, the Company considers the use of brand name topical corticosteroids [besides Impoyz (clobetasol), Bryhali (halobetasol), Lexette (halobetasol), Duobrii (halobetasol/tazarotene), Wyzora (calcipotriene/betamethasone), Impeklo (clobetasol), and branded halobetasol foam] when the patient has not tried and failed one generic prescription topical corticosteroid (e.g. clobetasol, desonide, triamcinolone, hydrocortisone, betamethasone) to be **not medically necessary.****

When Services Are Considered Investigational

Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.

Based on review of available data, the Company considers the use of Impoyz (clobetasol), Bryhali (halobetasol), Lexette (halobetasol), Duobrii (halobetasol/tazarotene), Wyzora (calcipotriene/betamethasone), and branded halobetasol foam for patients younger than 18 years of age or for any indication other than the treatment of moderate to severe plaque psoriasis to be **investigational.***

Based on review of available data, the Company considers the use of Impeklo (clobetasol) for patients younger than 18 years of age or who do not have a diagnosis of a corticosteroid-responsive dermatosis to be **investigational.***

Background/Overview

Topical corticosteroids possess anti-inflammatory, antipruritic, and vasoconstrictive properties and are generally used for the symptomatic relief of inflammation and/or pruritus associated with acute and chronic corticosteroid-responsive skin conditions. In the United States, these products are

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Topical Corticosteroids

Policy # 00318

Original Effective Date: 05/22/2013

Current Effective Date: 05/10/2021

divided into 7 groups based on potency with group 1 being super high potency corticosteroids and group 7 being the least potent.

Impoyz contains 0.025% clobetasol propionate cream and Impeklo contains 0.05% clobetasol propionate lotion. Many generic clobetasol propionate products are available including clobetasol propionate cream 0.05%, clobetasol propionate gel 0.05%, clobetasol propionate ointment 0.05%, and clobetasol propionate emollient base cream 0.05%. Bryhali, Lexette, and the branded halobetasol foam are 3 newer formulations of halobetasol propionate, a topical corticosteroid that is also available as a generic 0.05% cream and 0.05% ointment. Lexette and the branded generic product are a 0.05% foam formulation of halobetasol, and Bryhali is a 0.01% lotion formulation of halobetasol. All of these products are classified as super-high potency topical corticosteroids except Bryhali, which is classified as a high potency topical corticosteroid. The FDA has approved these products for the treatment of plaque psoriasis in adult patients.

Duobrii and Wyzora are each combination products indicated for the topical treatment of plaque psoriasis in adults. Duobrii contains halobetasol 0.01% and tazarotene 0.045% and Wyzora contains calcipotriene 0.005% and betamethasone 0.064%. Each of these components are available in generic form as separate products, which may provide a more cost effective treatment option.

In addition to the generic clobetasol and halobetasol products, other high potency topical corticosteroids are available in generic formulations. These include betamethasone dipropionate 0.5% cream, lotion, or ointment and desoximetasone cream, gel, or ointment. These generic alternatives provide an equally efficacious, yet cost effective alternative to the branded products.

Rationale/Source

The patient selection criteria presented in this policy takes into consideration clinical evidence or patient history that suggests the available generic topical corticosteroids will be ineffective or cause an adverse reaction to the patient. Based on a review of the data, in the absence of the above mentioned caveat, there is no advantage of using a brand name topical corticosteroid over the available generic topical corticosteroids. Generic drugs are considered to have equal bioavailability and efficacy in comparison to brand name drugs.

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Topical Corticosteroids

Policy # 00318

Original Effective Date: 05/22/2013

Current Effective Date: 05/10/2021

Impoz was studied in two double-blind, randomized, vehicle-controlled trials in 532 adult subjects with moderate to severe plaque psoriasis. Subjects were treated twice daily with Impoz or vehicle cream for 14 days. The primary endpoint was the proportion of subjects who achieved treatment success at day 15, defined as an Investigator Global Assessment (IGA) score of 0 (clear) or 1 (almost clear) with at least a 2-grade reduction from baseline. In trials 1 and 2, 30.2% and 30.1% of the Impoz group achieved the primary endpoint compared to approximately 9% and 9.7% of the vehicle group. Impoz was not compared to any of the many available alternative topical corticosteroid products, so no claims of superiority can be made.

Bryhali lotion was evaluated for the treatment of moderate to severe plaque psoriasis in two prospective, multicenter, randomized, double-blind clinical trials conducted in 430 adult subjects with moderate to severe plaque psoriasis that covered a body surface area between 3% and 12% (excluding the face, scalp, palms, soles, axillae, and intertriginous areas). Subjects applied Bryhali lotion or vehicle to all affected areas once daily for up to 8 weeks. The primary efficacy endpoint was the proportion of subjects with treatment success at week 8, where treatment success was defined as at least a 2-grade improvement from baseline in the IGA score and an IGA score equating to “clear” or “almost clear.” In trial 1, the primary endpoint was met in 37% of Bryhali patients and 8% of vehicle patients. In trial 2, the primary endpoint was met in 38% of Bryhali patients and 12% of vehicle patients. The treatment difference in trial 2 was not statistically significant.

Halobetasol foam was evaluated for the treatment of moderate to severe plaque psoriasis in two multicenter, randomized, double-blind, vehicle-controlled studies in 560 adult subjects with plaque psoriasis involving between 2% and 12% body surface area. Subjects applied halobetasol foam or vehicle to all affected areas twice daily for up to 14 consecutive days. The primary measure of efficacy was the overall treatment success, defined as the proportion of subjects who were cleared or almost cleared with at least a two-grade improvement from baseline at week 2 based on the IGA. In study 1, the primary endpoint was met in 25% of halobetasol patients and 4% of vehicle patients. In study 2, the primary endpoint was met in 31% of halobetasol patients and 7% of vehicle patients.

The safety and efficacy of Duobrii for the treatment of moderate to severe plaque psoriasis were assessed in two prospective, multicenter, randomized, double-blind clinical trials conducted in 418 subjects 18 years of age and older with moderate to severe plaque psoriasis that covered a BSA of 3-12%. Disease severity was determined by a 5-grade IGA. Subjects applied Duobrii or vehicle to all affected areas once daily for up to 8 weeks. The primary efficacy endpoint in both trials was the

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Topical Corticosteroids

Policy # 00318

Original Effective Date: 05/22/2013

Current Effective Date: 05/10/2021

proportion of subjects with treatment success at week 8. Treatment success was defined as at least a 2-grade improvement from baseline in the IGA score and an IGA score equating to “clear” or “almost clear.” In trial 1, 36% of patients in the Duobrii group had treatment success vs 7% in the vehicle group. In trial 2, 45% of patients in the Duobrii group had treatment success vs 13% in the vehicle group.

The safety and efficacy of Wyzora were evaluated in a randomized, multicenter, vehicle and active-comparator controlled clinical trial in adult subjects with mild to moderate plaque psoriasis. In the trial, 794 subjects were randomized to 1 of 3 treatment groups: Wyzora cream, vehicle cream, or calcipotriene/betamethasone dipropionate topical suspension, 0.005%/0.064%. The majority of subjects in the trial (81.7%) had disease of moderate severity at baseline, while 18.3% of subjects had disease of mild severity as determined by a 5-grade Physician’s Global Assessment (PGA) scale. The primary efficacy endpoint was the proportion of subjects with treatment success (i.e., at least a 2-grade improvement from baseline in the PGA score and a PGA score equating to “clear” or “almost clear”) at week 8. In the Wyzora group, 37.4% of patients achieved the primary endpoint vs 3.7% of patients in the vehicle group. This result was statistically significant. Additionally, Wyzora was non-inferior to the active comparator, calcipotriene/betamethasone dipropionate topical suspension.

The efficacy of Impeklo in psoriasis and atopic dermatitis has been demonstrated in two well-controlled clinical trials. The first trial was conducted in subjects with moderate to severe plaque psoriasis. Subjects were treated twice daily for 4 weeks with either Impeklo or vehicle lotion. At the end of treatment, 36.6% of subjects treated with Impeklo vs 0 treated with vehicle achieved treatment success defined as a score of none or very mild on the Global Severity scale of psoriasis. The second trial was conducted in subjects with moderate to severe atopic dermatitis. Subjects were treated twice daily for 2 weeks with either Impeklo or vehicle. At the end of treatment 42.7% of those treated with Impeklo vs 12.1% treated with vehicle achieved success defined as a score of none or very mild on the Global Severity scale of atopic dermatitis.

References

1. Impoyz [package insert]. Princeton, NJ. Promius Pharma. 11/2017
2. Express Scripts. Topical Corticosteroids Step Therapy Policy. 2/2018.
3. Comparison of representative topical corticosteroid preparations (classified according to the US system). UpToDate. 2018.

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Topical Corticosteroids

Policy # 00318

Original Effective Date: 05/22/2013

Current Effective Date: 05/10/2021

4. Express Scripts. Topical Corticosteroids Therapy Class Summary. 2/2017
5. Bryhali [package insert]. Valeant Pharmaceuticals. Bridgewater, NJ. 11/2018
6. Halobetasol propionate [package insert]. Mayne Pharma Greenville, NC.. 1/2019
7. Duobrii [package insert]. Valeant Pharmaceuticals. Bridgewater, NJ. 4/2019.
8. Wyzora [package insert]. MC2 Therapeutics Ltd. Charleston, SC. 1/2021
9. Impeklo [package insert]. Mylan Specialty L.P. Morgantown, WV. 5/2020.

Policy History

Original Effective Date: 05/22/2013

Current Effective Date: 05/10/2021

- | | |
|------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 05/02/2013 | Medical Policy Committee review |
| 05/22/2013 | Medical Policy Implementation Committee approval. New policy. |
| 05/01/2014 | Medical Policy Committee review |
| 05/21/2014 | Medical Policy Implementation Committee approval. No change to coverage. |
| 06/25/2015 | Medical Policy Committee review |
| 07/15/2015 | Medical Policy Implementation Committee approval. No change to coverage. |
| 06/30/2016 | Medical Policy Committee review |
| 07/20/2016 | Medical Policy Implementation Committee approval. No change to coverage |
| 07/06/2017 | Medical Policy Committee review |
| 07/19/2017 | Medical Policy Implementation Committee approval. No change to coverage |
| 07/05/2018 | Medical Policy Committee review |
| 07/11/2018 | Medical Policy Implementation Committee approval. Policy updated to include new drug, Impoyz. Added PA criteria for Impoyz and separated policy into step only, step/PA, PA only to address the PA added to Impoyz. |
| 04/04/2019 | Medical Policy Committee review |
| 04/24/2019 | Medical Policy Implementation Committee approval. Policy updated to include new drugs, Bryhali, Lexette, and branded halobetasol foam. Added PA criteria for new drugs. |
| 09/05/2019 | Medical Policy Committee review |
| 09/11/2019 | Medical Policy Implementation Committee approval. Policy updated to include new drug, Duobrii. |
| 09/03/2020 | Medical Policy Committee review |

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Topical Corticosteroids

Policy # 00318

Original Effective Date: 05/22/2013

Current Effective Date: 05/10/2021

09/09/2020 Medical Policy Implementation Committee approval. Added Halog to step therapy section.

04/01/2021 Medical Policy Committee review

04/14/2021 Medical Policy Implementation Committee approval. Added new drugs, Wyzora and Impeklo with relevant criteria. Minor edits to existing criteria for clarity.

Next Scheduled Review Date: 04/2022

***Investigational** – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:

- A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. Food and Drug Administration (FDA) and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or
- B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:
 1. Consultation with the Blue Cross and Blue Shield Association technology assessment program (TEC) or other nonaffiliated technology evaluation center(s);
 2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
 3. Reference to federal regulations.

****Medically Necessary** (or “Medical Necessity”) - Health care services, treatment, procedures, equipment, drugs, devices, items or supplies that a Provider, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury, disease or its symptoms, and that are:

- A. In accordance with nationally accepted standards of medical practice;
- B. Clinically appropriate, in terms of type, frequency, extent, level of care, site and duration, and considered effective for the patient's illness, injury or disease; and

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Topical Corticosteroids

Policy # 00318

Original Effective Date: 05/22/2013

Current Effective Date: 05/10/2021

- C. Not primarily for the personal comfort or convenience of the patient, physician or other health care provider, and not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient's illness, injury or disease.

For these purposes, “nationally accepted standards of medical practice” means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, Physician Specialty Society recommendations and the views of Physicians practicing in relevant clinical areas and any other relevant factors.

‡ Indicated trademarks are the registered trademarks of their respective owners.

NOTICE: If the Patient’s health insurance contract contains language that differs from the BCBSLA Medical Policy definition noted above, the definition in the health insurance contract will be relied upon for specific coverage determinations.

NOTICE: Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.